OTC ANDA approvals
This article was originally published in The Tan Sheet
Executive Summary
Wockhardt receives FDA approval for a generic version of Pfizer's H2 blocker Zantac (ranitidine) in a 75 mg OTC dose, the Mumbai, India-based pharmaceutical and biotech firm reports Feb. 27. The firm's U.S. branch expects to launch the drug "shortly." Wockhardt already has made 150 mg and 300 mg prescription doses of the H2 available in the U.S. "With the addition of the OTC version, we will now have the full range of ranitidine medications in the U.S.," Executive Director Lalit Kumar states. Separately, FDA approved an ANDA for loratadine 10 mg (equivalent to Schering-Plough's Claritin) for Canadian firm Apotex on Feb. 22, the agency reports...
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.